消息面上，据联邦制药官微消息，11月21至22日，中国研究型医院学会首届慢病防治暨三高(慢病)共管 平台建设大会在广西北海成功举办。会上，联邦制药重点展示了降糖系列产品布局，包括新近上市的利 拉鲁肽注射液"联邦优利泰"，以及预计明年上市的司美格鲁肽注射液"联邦优美泰"，这些产品的推出标 志着联邦制药在GLP-1靶点治疗领域取得重要进展。 值得一提的是，此前，联邦制药旗下子公司联邦生物与诺和诺德就UBT251达成独家许可协议。此次合 作不仅印证了UBT251的全球市场价值，还能借助诺和诺德的资源加速UBT251的全球开发进程。同时这 一合作也是联邦制药创新转型的重要成果，推动其GLP-1领域创新药与国际标准接轨，助力产品走向全 球近80个国家和地区的业务网络，提升国产GLP-1类药物的国际影响力。 联邦制药(03933)午前涨超4%，截至发稿，涨4.08%，报59.95港元，成交额3128.21万港元。 ...

Core Viewpoint - Federal Pharmaceutical (03933) has shown significant stock performance, rising over 4% following the successful presentation of its diabetes treatment products at a recent conference, indicating strong market interest and potential growth in the GLP-1 treatment sector [1] Group 1: Product Development - The company showcased its diabetes product lineup, including the recently launched liraglutide injection "Federal Yuli Tai" and the upcoming semaglutide injection "Federal Youmei Tai," marking important advancements in the GLP-1 target treatment area [1] - The collaboration between Federal Pharmaceutical's subsidiary, Federal Bio, and Novo Nordisk for the exclusive licensing of UBT251 highlights the global market potential of this product and aims to accelerate its development process [1] Group 2: Strategic Partnerships - The partnership with Novo Nordisk not only validates the global market value of UBT251 but also leverages Novo Nordisk's resources to enhance the product's development [1] - This collaboration represents a significant achievement in Federal Pharmaceutical's innovation transformation, aligning its GLP-1 innovative drugs with international standards and expanding its reach to nearly 80 countries and regions [1]